Mycophenolate Mofetil: Selective T Cell Inhibition

COVID-19 in posttransplant patients—report of 2 cases

“…Both cyclosporin-A and mycphenolate mofetil work by targeting the proliferation and differentiation of T cells. [3][4][5] It is notable that the number of T cells was significantly decreased in these 2 cases. T cell reduction is common in severe COVID-19 cases, 6 indicating coronavirus might mainly act on lymphocytes, especially T lymphocytes.…”

“…The immunosuppressive agents they took, including cyclosporin-A and mycphenolate mofetil, have been reported to increase the risk of opportunistic infection, including viral infection. [3][4][5] Whether or not these drugs could also increase the chances of COVID-19 infection, as an additional opportunistic infection, remains unknown. Both cyclosporin-A and mycphenolate mofetil work by targeting the proliferation and differentiation of T cells.…”

Prevention of Intraabdominal Adhesions by Local and Systemic Administration of Immunosuppressive Drugs

“…Therefore, production of IL-2 is blocked and proliferation signs of T-cells are inhibited (20, 21). Mycophenolate mofetil is a kind of pro-drug of mycophenolic acid (MPA) and fermentation products of Penicillium types (22). Mycophenolic acid is a potent inhibitor of inosine-monophosphate dehydrogenase, which is an important enzyme for de novo purine synthesis (23).…”

Sjogren’s syndrome with pulmonary nodular light chain deposition disease; response to mycophenolate mofetile

“…MMF preferentially binds to type II isoform of IMP dehydrogenase, expressed by activated lymphocytes. 8 MMF however could lead to immunosuppression through other mechanisms, including apoptosis of activated T-lymphocytes, and inhibition of adhesion molecule expression and lymphocyte recruitment. 9 Since both T and B cells have been suggested to have a pivotal role in the immunopathogensis of primary SS, 10,11 MMF may be a promising drug in the management of SS and the lymphoproliferative disorders associated with this syndrome.…”